News articles about Capricor Therapeutics (NASDAQ:CAPR) have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capricor Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.565501438857 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Pre-Open Movers 02/05: (CAPR) (EYES) (BG) Higher; (WFC) (DKS) (QCOM) Lower (more…) (streetinsider.com)
- Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy (finance.yahoo.com)
- BRIEF-Capricor Therapeutics Says FDA Has Granted CAP-1002 RMAT Designation (reuters.com)
- Zacks Investment Research Downgrades Capricor Therapeutics (CAPR) to Hold (americanbankingnews.com)
Capricor Therapeutics (NASDAQ:CAPR) traded down $0.06 during trading on Thursday, hitting $1.75. The stock had a trading volume of 225,589 shares, compared to its average volume of 652,584. The stock has a market cap of $44.48, a P/E ratio of -2.65 and a beta of -4.66. Capricor Therapeutics has a 52 week low of $0.63 and a 52 week high of $4.25.
A number of brokerages have issued reports on CAPR. Zacks Investment Research lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. HC Wainwright restated a “buy” rating and issued a $8.60 price objective (up from $6.50) on shares of Capricor Therapeutics in a report on Friday, January 26th.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2018/02/08/capricor-therapeutics-capr-receives-daily-media-sentiment-rating-of-0-13.html.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.